|
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma Clinical research trials and Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma. Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma clinical trial. Subjects typically recieve the finest healthcare available for their Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma  Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
For Condition: Chronic Lymphocytic Leukemia,adult non-Hodgkin's lymphoma
Status: Recruiting
Sponsor(s): Cancer Biotherapy Research Group ,
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining pentostatin and cyclophosphamide with rituximab in treating patients who have chronic lymphocytic leukemia or lymphocyticlymphoma.
Details: OBJECTIVES: - Determine the efficacy of pentostatin, cyclophosphamide, and rituximab, in terms of response rate, time to treatment failure, time to disease progression, durability of response, and overall survival, in patients with B-cell chronic lymphocytic leukemia or small B-cell lymphocytic lymphoma. - Determine the safety of this regimen, in terms of acute, subacute, and chronic toxicity, in patients treated with this regimen. OUTLINE: This is a multicenter study. Patients are stratified according to prior chemotherapy (no prior chemotherapy for chronic lymphocytic leukemia vs prior purine analog-based therapy [fludarabine or cladribine] but no alkylator therapy vs prior alkylator-based therapy [chlorambucil or cyclophosphamide] but no prior purine analog therapy vs prior therapy with alkylators and purine analogs, but not as combination therapy). - First course: Patients receive rituximab IV over 1-4 hours on days 1-3 and pentostatin IV over 10-30 minutes and cyclophosphamide IV over 30-60 minutes on day 1. - All subsequent courses: Patients receive rituximab IV over 60 minutes, pentostatin IV over 10-30 minutes, and cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 5 years. PROJECTED ACCRUAL: A total of 160-240 patients (40-60 per stratum) will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Diagnosis of B-cell chronic lymphocytic leukemia (CLL) or small B-cell lymphocytic lymphoma (SLL) with the following: - Lymph node biopsy interpreted as SLL or consistent with CLL or all of the following: - Peripheral lymphocyte count greater than 5,000/mm^3 with small to moderate peripheral lymphocytes and no more than 55% prolymphocytes - Bone marrow aspirate containing at least 30% lymphoid cells - Immunophenotypic evaluation of peripheral blood lymphocytes demonstrating monoclonality of B lymphocytes with all of the following: - CD19 or CD20 coexpressed with CD5 antigen in the absence of other pan-T- cell markers (e.g., CD2 or CD3) - Expression of CD23 on CLL cells or Dim B-cell expression of kappa or lambda light chains - Measurable disease with any of the following: - 1 or more lymph nodes at least 1.5 cm by CT scan - Splenomegaly by CT scan - Peripheral lymphocyte count greater than 5,000/mm3 with coexpression of CD5 and B-cell markers - Bone marrow aspirate with at least 30% lymphoid cells - No mantle cell lymphoma PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-2 Life expectancy - At least 2 years Hematopoietic - See Disease Characteristics - No immune thrombocytopenia - No hemolytic anemia Hepatic - Bilirubin no greater than 3 times upper limit of normal (ULN) - SGOT no greater than 3 times ULN (unless due to hemolysis or CLL) - No hepatitis Renal - Creatinine no greater than 1.5 times ULN Cardiovascular - No cardiac dysfunction - No New York Heart Association class III or IV heart disease - No myocardial infarction within the past month Other - HIV negative - No active acute or chronic infection - No immunosuppressive diseases - No autoimmune disorder - No secondary malignancy that is projected to limit life expectancy - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy - See Chemotherapy - No prior rituximab - At least 4 weeks since prior biologic therapy Chemotherapy - At least 4 weeks since prior chemotherapy - No prior combination chemotherapy and rituximab or other antibody therapy - No prior combination chemotherapy comprising an alkylating agent and a purine nucleoside analog (i.e., cyclophosphamide or chlorambucil in combination with fludarabine, cladribine, or pentostatin) - No prior pentostatin Endocrine therapy - At least 4 weeks since prior corticosteroids - No concurrent supra-physiologic doses of corticosteroids Radiotherapy - At least 4 weeks since prior radiotherapy Surgery - At least 4 weeks since prior major surgery Other - No concurrent immunosuppressive therapy (e.g., cyclosporine)
Total Enrollment:
Location and Contact Information:
Overall Study Official:
RobertDillman, Study Chair, Hoag Memorial Hospital Presbyterian
Hoag Memorial Hospital Presbyterian *Recruiting*
Newport Beach, California, 92658
United States
Recruiting Robert Dillman 949-760-2091
Additional Information:
Study ID Numbers: CDR0000258096; SUPEREN-CBRG-NIP-0201,CBRG-NIP-0201,NCI-V02-1712
Study Start Date:
Record last reviewed: November 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00049413
Other Chronic Lymphocytic Leukemia Studies:
1. Phase I Study of Anti-Tac(Fv)-PE38 (LMB-2), a Recombinant Single-Chain Immunotoxin for Treatment of Tac-Expressing Malignancies
2. Tipifarnib in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
3. Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
4. Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia
5. Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer
Related Studies:
Other Chronic Lymphocytic Leukemia Clinical Trials
Other California Clinical Trials
Other Newport Beach Clinical Trials
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
|
|
|
|
|
|
|
|
